User: Guest  Login
Title:

Atezolizumab and bevacizumab with transarterial chemoembolization in hepatocellular carcinoma: the DEMAND trial protocol.

Document type:
Article; Journal Article; Review
Author(s):
Ben Khaled, Najib; Seidensticker, Max; Ricke, Jens; Mayerle, Julia; Oehrle, Bettina; Rössler, Daniel; Teupser, Daniel; Ehmer, Ursula; Bitzer, Michael; Waldschmidt, Dirk; Fuchs, Martin; Reuken, Philipp A; Lange, Christian M; Wege, Henning; Kandulski, Arne; Dechêne, Alexander; Venerito, Marino; Berres, Marie-Luise; Luedde, Tom; Kubisch, Ilja; Reiter, Florian P; De Toni, Enrico N
Abstract:
The combination of the anti-PD-L1 antibody atezolizumab and the anti-VEGF bevacizumab is the first approved immunotherapeutic regimen for first-line therapy in patients with unresectable hepatocellular carcinoma (HCC), currently approved in more than 80 countries. The efficacy and tolerability of this regimen suggest that the use of atezolizumab + bevacizumab could be extended to the treatment of patients with intermediate-stage HCC in combination with transarterial chemoembolization (TACE). The...     »
Journal title abbreviation:
Future Oncol
Year:
2022
Journal volume:
18
Journal issue:
12
Pages contribution:
1423-1435
Fulltext / DOI:
doi:10.2217/fon-2021-1261
Pubmed ID:
http://view.ncbi.nlm.nih.gov/pubmed/35081747
Print-ISSN:
1479-6694
TUM Institution:
1404; 595; Klinik und Poliklinik für Innere Medizin II, Gastroenterologie
 BibTeX